Journal of Hepatology 2015-06-01

Pharmacological activation of aldehyde dehydrogenase 2 by Alda-1 reverses alcohol-induced hepatic steatosis and cell death in mice.

Wei Zhong, Wenliang Zhang, Qiong Li, Guoxiang Xie, Qian Sun, Xiuhua Sun, Xiaobing Tan, Xinguo Sun, Wei Jia, Zhanxiang Zhou

Index: J. Hepatol. 62 , 1375-81, (2015)

Full Text: HTML

Abstract

Effective therapies for alcoholic liver disease are currently unavailable. The present study tested the efficacy of Alda-1, a specific aldehyde dehydrogenase 2 (ALDH2) activator, in treating alcoholic liver disease.Male C57BL/6J mice were exposed to alcohol for a time-course study on aldehyde metabolism. The specificity and efficacy of Alda-1 on activating hepatic ALDH2 and aldehyde clearance were determined by acute treatments. Then, mice were fed alcohol for 8 weeks with Alda-1 administration for the last 10 days to test the therapeutic potential of Alda-1. Lastly, H4IIEC3 cells were treated with ethanol, acetaldehyde, or 4-hydroxynonenal to define the link between aldehydes and hepatotoxicity.Alcohol feeding for 8 weeks induced hepatic ALDH2 dysfunction and aldehyde accumulation. One dose of Alda-1 administration elevated hepatic ALDH activity, which was blocked by the specific ALDH2 inhibitor, daidzin. Alda-1 accelerated acetaldehyde clearance after acute alcohol intoxication. Alda-1 treatment in the 8-week alcohol feeding model reversed liver damage along with reduction of hepatic aldehydes. Alda-1 re-activated transcription factors, upregulated fatty acid oxidation enzymes, and reversed steatosis. Alcohol-induced endoplasmic reticulum stress and apoptotic cell death were also attenuated by Alda-1. Acetaldehyde or 4-hydroxynonenal treatment to H4IIEC3 cells inactivated transcription factors and induced endoplasmic reticulum stress and apoptosis, while ethanol per se showed limited effects.Pharmacological activation of ALDH2 by Alda-1 reversed alcoholic steatosis and apoptosis through accelerating aldehyde clearance. This study indicates that ALDH2 is a promising molecular target and Alda-1 has therapeutic potential for treating alcoholic liver disease.Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.


Related Compounds

Related Articles:

The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.

2015-01-01

[Drug Des. Devel. Ther. 9 , 1627-52, (2015)]

Activation of Tomato Bushy Stunt Virus RNA-Dependent RNA Polymerase by Cellular Heat Shock Protein 70 Is Enhanced by Phospholipids In Vitro.

2015-05-01

[J. Virol. 89(10) , 5714-23, (2015)]

Caveolin-1 deficiency induces a MEK-ERK1/2-Snail-1-dependent epithelial-mesenchymal transition and fibrosis during peritoneal dialysis.

2015-01-01

[EMBO Mol. Med. 7(1) , 102-23, (2015)]

Inducible, tightly regulated and growth condition-independent transcription factor in Saccharomyces cerevisiae.

2014-01-01

[Nucleic Acids Res. 42(17) , e130, (2014)]

Co-ordinated brain and craniofacial development depend upon Patched1/XIAP regulation of cell survival.

2015-02-01

[Hum. Mol. Genet. 24(3) , 698-713, (2015)]

More Articles...